Literature DB >> 8392403

Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril.

N E Cameron1, M A Cotter, S Robertson.   

Abstract

The effect of treatment of rats with the angiotensin converting enzyme inhibitor lisinopril after 5 weeks of untreated streptozotocin-diabetes was examined by daily monitoring of sciatic motor conduction velocity to tibialis anterior muscle. Diabetes produced a 31.5% decrease in conduction velocity (P < 0.001). Lisinopril treatment caused a progressive improvement which was significant after 3 days (P = 0.002), full normalization being achieved by 6 days (P < 0.0001). After 7 days of treatment there followed a 7-day washout period in which no lisinopril was given. During this time conduction velocity declined to untreated diabetic levels over 3 days. A subsequent treatment period resulted in complete normalization of conduction velocity within 2 days (P < 0.0001). Thus, the marked functional effects seen for vasodilator treatment with lisinopril suggest that angiotension converting enzyme inhibitors may have potential therapeutic value in the treatment of diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392403     DOI: 10.1007/bf00572874

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  10 in total

Review 1.  Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system.

Authors:  K C Tomlinson; S M Gardiner; R A Hebden; T Bennett
Journal:  Pharmacol Rev       Date:  1992-03       Impact factor: 25.468

2.  Sural nerve oxygen tension in diabetes.

Authors:  P G Newrick; A J Wilson; J Jakubowski; A J Boulton; J D Ward
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

3.  Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na(+)-K(+)-ATPase activity, and vascular supply in STZ-D rats.

Authors:  N E Cameron; M A Cotter; K Ferguson; S Robertson; M A Radcliffe
Journal:  Diabetes       Date:  1991-12       Impact factor: 9.461

4.  The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.

Authors:  N E Cameron; M B Leonard; I S Ross; P H Whiting
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

5.  Variations in motor conduction velocity produced by acute changes of the metabolic state in diabetic patients.

Authors:  G Gregersen
Journal:  Diabetologia       Date:  1968-11       Impact factor: 10.122

6.  Chronic low frequency electrical activation for one week corrects nerve conduction velocity deficits in rats with diabetes of three months duration.

Authors:  N E Cameron; M A Cotter; S Robertson
Journal:  Diabetologia       Date:  1989-10       Impact factor: 10.122

7.  The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.

Authors:  N E Cameron; M A Cotter; S Robertson
Journal:  Q J Exp Physiol       Date:  1989-11

8.  Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats.

Authors:  N E Cameron; M A Cotter; S Robertson
Journal:  Diabetologia       Date:  1992-01       Impact factor: 10.122

9.  Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits.

Authors:  N E Cameron; M A Cotter; P A Low
Journal:  Am J Physiol       Date:  1991-07

10.  Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy.

Authors:  R R Tuck; J D Schmelzer; P A Low
Journal:  Brain       Date:  1984-09       Impact factor: 13.501

  10 in total
  7 in total

Review 1.  The role of axonal cytoskeleton in diabetic neuropathy.

Authors:  W G McLean
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

2.  Reversal of peripheral nerve conduction and perfusion deficits by the free radical scavenger, BM15.0639, in diabetic rats.

Authors:  N E Cameron; M A Cotter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

3.  Early vs. late intervention of high fat/low dose streptozotocin treated C57Bl/6J mice with enalapril, α-lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints.

Authors:  Matthew S Yorek; Alexander Obrosov; Hanna Shevalye; Lawrence J Coppey; Randy H Kardon; Mark A Yorek
Journal:  Neuropharmacology       Date:  2016-12-23       Impact factor: 5.250

Review 4.  The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.

Authors:  Toomas Podar; Jaakko Tuomilehto
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats.

Authors:  N E Cameron; M A Cotter; V Archibald; K C Dines; E K Maxfield
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

6.  Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity.

Authors:  M A Cotter; N E Cameron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

7.  Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice.

Authors:  Aurore Danigo; Mohamad Nasser; Flavien Bessaguet; James Javellaud; Nicole Oudart; Jean-Michel Achard; Claire Demiot
Journal:  Cardiovasc Diabetol       Date:  2015-02-18       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.